Real-World Data of Patients with <i>BRAF</i> V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil.

The mOS was higher in the GPC subgroup ( Figure 2 A), although this difference did not reach statistical significance (GPC mOS: 7.6 months, PPC mOS: 4.2 months; HR 1.64 [95% CI 0.65–4.10, p = 0.3]).

also in 111,027 other papers